Rheumatology is branch of medicine that deals with the diagnosis and treatment of disorders of connective tissues and joints, many of which are now known to be immune mediated conditions.
Optimising anti-TNF treatment using biosimilars
Biosimilars are uniquely placed to change clinical practice in the fields of gastroenterology, rheumatology, and dermatology. The adoption of biosimilars can improve patient access to the most appropriate treatment, at the optimum time, to ensure the best possible long-term disease outcomes.
Rheumatic diseases can be caused by trauma, heredity, genetic abnormality, autoimmune disease, or another underlying condition such as cancer. There are more than 150 different types of rheumatic disorders, including arthritis, rheumatoid and osteoarthritis, gout and lupus.
Related news and insights
AbbVie has announced that the European Union's European Commission has approved Skyrizi (risankizumab) for the treatment of adults with active psoriatic arthritis. Psoriatic arthritis is a systemic inflammatory disease that impacts the skin and joints, affecting approximately 30 percent of patients with psoriasis.
AbbVie announced results from new post-hoc analyses from the Phase III SELECT-PsA 1 and SELECT-PsA 2 trials assessing the efficacy of upadacitinib (Rinvoq) on axial symptoms in adult patients with active psoriatic arthritis (PsA) and axial involvement.
Olumiant (baricitinib) from Eli Lilly and Incyte, maintained a consistent safety profile in a long-term, integrated safety analysis of patients with rheumatoid arthritis (RA) who received Olumiant for 14,744 patient years of exposure, in line with previously published findings.